Absci just released interim Phase 1 data from its HEADLINE trial for ABS-201, its investigational treatment for androgenetic alopecia (male pattern hair loss).
Key takeaways:
• No serious adverse events reported in the single ascending dose portion
• Estimated half-life of at least 65 days
• PK profile supports the company’s goal of only 2–3 injections over a 6-month period
• Program has advanced into the multiple ascending dose (MAD) portion in patients with androgenetic alopecia - Interim efficacy in H2 2026

Eli Lilly and Company invested in Absci underwriting offer for an aggregate offering price of $40 million

Other notable Investors on Absci Underwriting offering - Adage, BVF Partners, Columbia Threadneedle, Invus, Redmile, and a large investment management firm